NYSE: CVSCvs Health Corp Stock
$74.00+0.52 (+0.71%)
Updated Sep 17, 2025
CVS Price
$74.00
Fair Value Price
N/A
Market Cap
$93.86B
52 Week Low
$43.56
52 Week High
$75.55
P/E
20.56x
P/B
1.21x
P/S
0.23x
PEG
0.67x
Dividend Yield
1.8%
Revenue
$386.64B
Earnings
$4.53B
Gross Margin
13.8%
Operating Margin
2.48%
Profit Margin
1.2%
Debt to Equity
2.34
Operating Cash Flow
$8B
Beta
0.5
Next Earnings
Oct 29, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CVS Overview
CVS Health Corporation owns CVS Pharmacy, a retail pharmacy chain, CVS Caremark, a pharmacy benefits manager, and Aetna, a health insurance provider, among many other brands. The company was founded in 1963 and is headquartered in Woonsocket, RI.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CVS's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Healthcare Plan
Industry Rating
C
CVS
Ranked#2 of 10
Ranked#2 of 10
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $296.59 | B | |
| $16.68 | C | |
| $308.48 | C |
Be the first to know about important CVS news, forecast changes, insider trades & much more!
CVS News
Overview
Due Diligence Score
–
Industry Average (39)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CVS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CVS ($74.00) is trading above its intrinsic value of $63.63, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CVS is good value based on its earnings relative to its share price (20.56x), compared to the US market average (37.36x)
P/E vs Market Valuation
CVS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more CVS due diligence checks available for Premium users.
Valuation
CVS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
20.56x
Industry
14.71x
Market
37.36x
CVS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CVS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CVS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.21x
Industry
2.02x
CVS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CVS price to earnings growth (PEG)
For valuing profitable companies with growth potential
CVS is good value based... subscribe to Premium to read more.
PEG Value Valuation
CVS's financial health
Profit margin
Revenue
$98.9B
Net Income
$1.0B
Profit Margin
1%
CVS's Earnings (EBIT) of $9.60B... subscribe to Premium to read more.
Interest Coverage Financials
CVS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$258.3B
Liabilities
$180.8B
Debt to equity
2.34
CVS's short-term liabilities ($94.16B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CVS's long-term liabilities ($86.63B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CVS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CVS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.9B
Investing
-$1.0B
Financing
$806.0M
CVS's operating cash flow ($7.57B)... subscribe to Premium to read more.
Debt Coverage Financials
CVS vs Healthcare Plan Stocks
Cvs Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.